60 day FRN

Attachment 2 - 60 Day FRN.pdf

Insurance Coverage, Employment Status, and Copayments/Deductibles Faced by Young Women Diagnosed with Breast Cancer

60 day FRN

OMB: 0920-1123

Document [pdf]
Download: pdf | pdf
50288

Federal Register / Vol. 80, No. 160 / Wednesday, August 19, 2015 / Notices
TABLE 1—PRODUCT CANCELLATIONS—Continued
EPA Registration No.

8845–125
8845–126
8845–127
8845–128

Product name

..................................................
..................................................
..................................................
..................................................

Hot
Hot
Hot
Hot

Table 2 of this unit includes the
names and addresses of record for all
the registrants of the products in Table
1 of this unit, in sequence by EPA
company number. This number
corresponds to the first part of the EPA
registration numbers of the products
listed in Table 1 of this unit.

TABLE 2—REGISTRANTS OF
CANCELLED PRODUCTS
EPA Company
No.

Company name and address

8845 ...............

Spectrum Group, A Division
of United Industries, 1
Rider Trail Plaza Drive,
Suite 300, Earth City, MO
63045.

III. Summary of Public Comments
Received and Agency Response to
Comments
During the public comment period
provided, EPA received no comments in
response to the March 13, 2013 Federal
Register (78 FR 15949) (FRL–9379–4)
notice announcing the Agency’s receipt
of the request for voluntary cancellation
of products listed in Table 1 of Unit II.
IV. Cancellation Order

tkelley on DSK3SPTVN1PROD with NOTICES

Pursuant to FIFRA section 6(f) (7
U.S.C. 136d(f)), EPA hereby approves
the requested cancellation of the
registrations identified in Table 1 of
Unit II. Accordingly, the Agency hereby
orders that the product registrations
identified in Table 1 of Unit II are
canceled. The effective date of the
cancellations that are the subject of this
notice is August 19, 2015. Any
distribution, sale, or use of existing
stocks of the products identified in
Table 1 of Unit II in a manner
inconsistent with any of the provisions
for disposition of existing stocks set
forth in Unit VI will be a violation of
FIFRA.
V. What is the Agency’s authority for
taking this action?
Section 6(f)(1) of FIFRA (7 U.S.C.
136d(f)(1)) provides that a registrant of
a pesticide product may at any time
request that any of its pesticide
registrations be canceled or amended to
terminate one or more uses. FIFRA

VerDate Sep<11>2014

19:45 Aug 18, 2015

Jkt 235001

Shot
Shot
Shot
Shot

Sudden
Sudden
Sudden
Sudden

Death
Death
Death
Death

Brand
Brand
Brand
Brand

Mouse Killer ............................................................
Rat Killer 1 ..............................................................
Mouse and Rat Killer ..............................................
Mouse Killer Bait Station ........................................

further provides that, before acting on
the request, EPA must publish a notice
of receipt of any such request in the
Federal Register. Thereafter, following
the public comment period, the EPA
Administrator may approve such a
request. The notice of receipt for this
action was published for comment in
the Federal Register of March 13, 2013
(78 FR 15949). The comment period
closed on April 12, 2013.
VI. Provisions for Disposition of
Existing Stocks
Existing stocks are those stocks of
canceled pesticide products that are in
the United States and that were
appropriately packaged, labeled, and
released for shipment prior to the
effective date of cancellation of the
underlying registration. The existing
stocks provisions for the products
subject to this order are as follows.
The registrant is prohibited from
selling or distributing existing stocks
above as of August 19, 2015, except for
export in accordance with FIFRA
section 17 (7 U.S.C. 136o), or proper
disposal. Persons other than the
registrant may sell, distribute, or use
existing stocks of products listed above
until existing stocks are exhausted,
provided that such sale, distribution, or
use is consistent with the terms of the
previously approved labeling on, or that
accompanied, the canceled products.
Authority: 7 U.S.C. 136 et seq.
Dated: July 27, 2015.
Richard P. Keigwin, Jr.,
Director, Pesticide Re-Evaluation Division,
Office of Pesticide Programs.
[FR Doc. 2015–20500 Filed 8–18–15; 8:45 am]
BILLING CODE 6560–50–P

FEDERAL MARITIME COMMISSION
Notice of Agreements Filed
The Commission hereby gives notice
of the filing of the following agreement
under the Shipping Act of 1984.
Interested parties may submit comments
on the agreement to the Secretary,
Federal Maritime Commission,
Washington, DC 20573, within twelve
days of the date this notice appears in
the Federal Register. A copy of the
agreement is available through the

PO 00000

Frm 00027

Fmt 4703

Chemical name

Sfmt 4703

Bromethalin.
Bromethalin.
Bromethalin.
Bromethalin.

Commission’s Web site (www.fmc.gov)
or by contacting the Office of
Agreements at (202) 523–5793 or
[email protected].
Agreement No.: 012301–002.
Title: Siem Car Carrier Pacific AS/
Volkswagen Konzernlogistik GmBH &
Co. OHG Space Charter Agreement.
Parties: Siem Car Carrier Pacific AS
and Volkswagen Konzernlogistik GmBH
& Co. OHG.
Filing Party: Ashley W. Craig, Esq.,
and Elizabeth K. Lowe, Esq.; Venable
LLP; 575 Seventh Street NW.,
Washington, DC 20004.
Synopsis: The amendment changes
the name of the Volkswagen party to the
Agreement.
By Order of the Federal Maritime
Commission.
Dated: August 14, 2015.
Rachel E. Dickon,
Assistant Secretary.
[FR Doc. 2015–20489 Filed 8–18–15; 8:45 am]
BILLING CODE P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–15–15BDJ; Docket No. CDC–2015–
0070]

Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:

The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies to take this opportunity to
comment on proposed and/or
continuing information collections, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comment on the proposed information
collection request entitled ‘‘Breast
Cancer in Young Women Survey’’,

SUMMARY:

E:\FR\FM\19AUN1.SGM

19AUN1

Federal Register / Vol. 80, No. 160 / Wednesday, August 19, 2015 / Notices
which is designed to assess insurance
coverage, employment status and out-ofpocket health care expenses among
young women diagnosed with breast
cancer and to look at the relationship
between these variables and treatment
decisions.
Written comments must be
received on or before October 19, 2015.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2015–
0070 by any of the following methods:
Federal eRulemaking Portal:
Regulation.gov. Follow the instructions
for submitting comments. Mail: Leroy A.
Richardson, Information Collection
Review Office, Centers for Disease
Control and Prevention, 1600 Clifton
Road NE., MS–D74, Atlanta, Georgia
30329.
Instructions: All submissions received
must include the agency name and
Docket Number. All relevant comments
received will be posted without change
to Regulations.gov, including any
personal information provided. For
access to the docket to read background
documents or comments received, go to
Regulations.gov.
DATES:

Please note: All public comment should be
submitted through the Federal eRulemaking
portal (Regulations.gov) or by U.S. mail to the
address listed above.

tkelley on DSK3SPTVN1PROD with NOTICES

FOR FURTHER INFORMATION CONTACT:

To

request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact the Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE., MS–D74, Atlanta,
Georgia 30329; phone: 404–639–7570;
Email: [email protected].
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires Federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including

VerDate Sep<11>2014

19:14 Aug 18, 2015

Jkt 235001

whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology; and (e) estimates of capital
or start-up costs and costs of operation,
maintenance, and purchase of services
to provide information. Burden means
the total time, effort, or financial
resources expended by persons to
generate, maintain, retain, disclose or
provide information to or for a Federal
agency. This includes the time needed
to review instructions; to develop,
acquire, install and utilize technology
and systems for the purpose of
collecting, validating and verifying
information, processing and
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
a collection of information, to search
data sources, to complete and review
the collection of information; and to
transmit or otherwise disclose the
information.
Proposed Project
Insurance Coverage, Employment
Status, and Copayments/Deductibles
Faced by Young Women Diagnosed with
Breast Cancer—New—National Center
for Chronic Disease Prevention and
Health Promotion (NCCDPHP), Centers
for Disease Control and Prevention
(CDC).
Background and Brief Description
The Education and Awareness
Requires Learning Young (EARLY) Act
of 2009, which is outlined in section
10413 of the Patient Protection and
Affordable Care Act, authorizes the CDC
to fund research and initiatives that
increase knowledge of breast health and
breast cancer among women,
particularly among those under the age
of 40. The EARLY Act along with
section 301 of the Public Health Service
Act authorizes the CDC to conduct
research that will inform the prevention
of physical and mental diseases such as
breast cancer, and serves as the main
basis for this data collection activity.
Research indicates that young women
diagnosed with breast cancer face many
barriers accessing high-quality breast
cancer care and treatment. These
barriers are compounded by the
multiple roles that these young women
serve in society including parenting
young children, developing a career,

PO 00000

Frm 00028

Fmt 4703

Sfmt 4703

50289

and completing their education.
Treatment decisions can be complicated
for young women with breast cancer.
Some research indicates that
employment status, financial stability,
and insurance coverage are variables
that affect treatment compliance, access
to quality care, and ultimately quality of
life for young women with breast
cancer. However, to date, no
comprehensive assessment has been
conducted to examine breast cancer care
and treatment for young women.
CDC propose to address this gap by
answering the following two research
questions: (1) What are young, female
breast cancer survivors experiencing
after their diagnosis in terms of (a)
continuation of insurance coverage,
access to care, and quality of care; (b)
changes in employment status after
breast cancer diagnosis; and (c) out-ofpocket medical costs? (2) What factors
affect young breast cancer survivors’
access to comprehensive, high quality
care?
To answer these research questions,
CDC is sponsoring a study to collect
information from two groups of breast
cancer survivors: One randomly drawn
from state-based cancer registries
(Sample 1), the other a self-selected
convenience sample drawn from two
advocacy organizations (Sample 2).
Sample 1 will include up to 1,750
young (diagnosed between the ages of
18 and 39), female breast cancer
survivors diagnosed for the first time
with breast cancer 12 months before the
survey is fielded. Respondents will be
recruited through approximately four
state-based central cancer registries.
These respondents will be asked to
complete a mail-in or web-based
questionnaire. Self-reported survey data
from Sample 1 will be supplemented by
data maintained by their state’s cancer
registry, including information about
tumor characteristics, date of diagnosis,
and stage. The linked survey and cancer
registry data will be used to answer
research question #2 (What factors affect
young breast cancer survivors’ access to
comprehensive, high quality care?).
Sample 2 will include a nation-wide
convenience sample of 2,000 female
breast cancer survivors diagnosed
between the ages of 18 and 49 who are
associated with one of two breast cancer
advocacy groups (Living Beyond Breast
Cancer and Young Survival Coalition).
This cohort will exclude individuals
from Sample 1 and will not be linked
to any other data source.
Comparing results between Sample 1
and Sample 2 will help us address these
additional research questions: (1) How
generalizable are the results from the
convenience Sample 2? (2) Are there

E:\FR\FM\19AUN1.SGM

19AUN1

50290

Federal Register / Vol. 80, No. 160 / Wednesday, August 19, 2015 / Notices

differences between young breast cancer
survivors based on the length of time
that has elapsed from cancer diagnosis?
(3) Do the experiences and barriers
faced by women diagnosed between 18
and 39 years of age (Samples 1 and 2)
differ from those of women diagnosed
between 40 and 44 years of age and 45
and 49 years of age (Sample 2)? This
comparison will also help CDC explore
whether drawing a convenience sample
from survivorship groups will be a
methodologically legitimate, less
expensive method to recruit
respondents for future breast cancer
survivor surveys.
The target number of responses for the
overall study will result in up to 3,750

completed surveys. Respondents will be
asked to complete a questionnaire,
which is estimated to take about 22
minutes. Sample 1 respondents will
have the option of completing a
hardcopy questionnaire or an online
questionnaire. Sample 2 respondents
will complete the questionnaire online.
Demographic information will be
collected from all patients who
participate in the study.
Findings from this study will be used
to identify interventions to ameliorate or
eliminate existing barriers to treatment
so that young women have access to
high quality breast cancer treatment and
care. Study findings will be
disseminated through reports,

presentations, and publications. Results
will also be used by participating sites,
CDC, and other federal agencies to
improve care and services provided to
young women diagnosed with breast
cancer.
OMB approval is requested for three
years and the burden table presents
annuitized estimates. CDC’s data
collection contractor will securely
maintain identifiable information from
respondents recruited from state
registries (Sample 1). No identifiable
information will be collected by CDC.
Participation is voluntary and there are
no costs to respondents other than their
time.

ESTIMATED ANNUALIZED BURDEN HOURS

Sample 1—Breast Cancer survivors included in one of as
many as four state registries.
Sample 2—Breast Cancer survivors associated with advocacy groups.
Total ....................................

Number of
responses per
respondent

Breast Cancer in Young Women Survey .......
(Mail or web-based version questionnaire) ....

583

1

22/60

214

Breast Cancer in Young Women Survey .......
(Web-based questionnaire) .............................

667

1

22/60

244

.........................................................................

....................

........................

....................

458

Form name

Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
[FR Doc. 2015–20479 Filed 8–18–15; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–15–15NR]

tkelley on DSK3SPTVN1PROD with NOTICES

Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) has submitted the
following information collection request
to the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995. The notice for
the proposed information collection is
published to obtain comments from the
public and affected agencies.
Written comments and suggestions
from the public and affected agencies
concerning the proposed collection of
information are encouraged. Your
comments should address any of the
following: (a) Evaluate whether the

VerDate Sep<11>2014

19:14 Aug 18, 2015

Average
burden per
response
(in hours)

Number of
respondents

Type of respondent

Jkt 235001

proposed collection of information is
necessary for the proper performance of
the functions of the agency, including
whether the information will have
practical utility; (b) Evaluate the
accuracy of the agencies estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected; (d) Minimize the burden of
the collection of information on those
who are to respond, including through
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and (e) Assess information
collection costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570 or
send an email to [email protected]. Written
comments and/or suggestions regarding
the items contained in this notice
should be directed to the Attention:
CDC Desk Officer, Office of Management
and Budget, Washington, DC 20503 or
by fax to (202) 395–5806. Written
comments should be received within 30
days of this notice.

PO 00000

Frm 00029

Fmt 4703

Sfmt 4703

Total burden
(in hours)

Proposed Project
Capacity Building Assistance
Program: Assessment and Quality
Control—New—National Center for
HIV/AIDS, Viral Hepatitis, STD, and TB
Prevention (NCHHSTP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
The CDC is requesting the Office of
Management and Budget (OMB) to grant
a three-year approval to collect data that
comprises Health Professional
Application for Training (HPAT), the
Training Follow-up Instrument, the
Technical Assistance (TA) Satisfaction
Instrument, and the Capacity Building
Assistance (CBA) Key Informant
Interview. The purpose of this
information collection is to assess the
degree to which the CDC’s CBA program
meets the needs of its consumers in
order to enhance its capacity building
strategy over time. The HPAT serves as
the official application form for training
and technical activities conducted by
the Sexually Transmitted Disease (STD)/
Human immunodeficiency virus (HIV)
Prevention Training Centers’ (PTCs)
grantees and the HIV Capacity Building
Assistance (CBA providers) grantees
funded by the (CDC). The HPAT form is
currently approved under OMB Control
Number 0920–0995 and expires on
October 31, 2016.

E:\FR\FM\19AUN1.SGM

19AUN1


File Typeapplication/pdf
File Modified2015-08-19
File Created2015-08-19

© 2024 OMB.report | Privacy Policy